Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoFOL-R: Perioperative vs Adjuvant FOLFIRINOX in Pancreatic Cancer
NCT05529940Phase 3Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, folinic acid, irinotecan, oxaliplatin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Seoul National University Hospital. Started Apr 2023; status: recruiting.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05529940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529940.